Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oxyuranus venom toxins are a complex and highly lethal suite of proteins and peptides found in the venom of taipan snakes, including the Coastal Taipan (Oxyuranus scutellatus), Inland Taipan (Oxyuranus microlepidotus), and Western Desert Taipan (Oxyuranus temporalis). These toxins are primarily categorized into several major families: presynaptic phospholipase A2 (PLA2) neurotoxins, postsynaptic three-finger toxins (3FTxs), and potent prothrombin activators. The PLA2 neurotoxins, such as taipoxin and paradoxin, act by inhibiting the release of acetylcholine at the neuromuscular junction, leading to progressive and often irreversible respiratory paralysis. Postsynaptic 3FTxs competitively inhibit nicotinic acetylcholine receptors, further contributing to neuromuscular blockade. Many taipan venoms also contain potent prothrombin activators, like the oscutarin-C complex, which induce rapid venom-induced consumption coagulopathy (VICC) by converting prothrombin to thrombin. This coagulopathy leads to the depletion of clotting factors and a high risk of systemic hemorrhage. Other components include natriuretic peptides that cause hypotension and Kunitz-type inhibitors. While these toxins are the causative agents of severe envenomation, they are also the specific targets of therapeutic antivenoms. Antivenoms utilize purified antibody fragments to bind and neutralize the biological activity of these toxins. Understanding the homology and variation of these toxins across Oxyuranus species is critical for the development of effective, cross-reactive treatments.
Antivenom-mediated neutralization via binding of F(ab')2 or IgG fragments to toxin epitopes, preventing interaction with physiological targets such as the presynaptic membrane or prothrombin.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Oxyuranus venom toxins.